Cargando…
Proteomics‐based identification of the role of osteosarcoma amplified‐9 in hepatocellular carcinoma recurrence
Hepatocellular carcinoma (HCC) is one of the most prevalent malignancies; its recurrence is associated with high mortality and poor recurrence‐free survival and is affected by multisystem and multilevel pathological changes. To identify the key proteins associated with tumor recurrence and the under...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9315138/ https://www.ncbi.nlm.nih.gov/pubmed/35429130 http://dx.doi.org/10.1002/hep4.1952 |
_version_ | 1784754487595892736 |
---|---|
author | Wei, Xuyong Yang, Mengfan Pan, Binhua Zhang, Xiaobing Lin, Hanchao Li, Wangyao Shu, Wenzhi Wang, Kun Khan, Abdul Rehman Zhang, Xuanyu Cen, Beini Xu, Xiao |
author_facet | Wei, Xuyong Yang, Mengfan Pan, Binhua Zhang, Xiaobing Lin, Hanchao Li, Wangyao Shu, Wenzhi Wang, Kun Khan, Abdul Rehman Zhang, Xuanyu Cen, Beini Xu, Xiao |
author_sort | Wei, Xuyong |
collection | PubMed |
description | Hepatocellular carcinoma (HCC) is one of the most prevalent malignancies; its recurrence is associated with high mortality and poor recurrence‐free survival and is affected by multisystem and multilevel pathological changes. To identify the key proteins associated with tumor recurrence and the underlying mechanisms, proteomic profiling of tumor specimens from early recurrence and nonrecurrence patients was performed in this study. Proteomics was applied to identify differentially expressed proteins during the early recurrence of HCC after surgery. Osteosarcoma amplified‐9 (OS‐9) was discovered, and the correlation between OS‐9 expression and the clinicopathological characteristics of patients was analyzed. Invasion and migration were examined in SMMC‐7721 cells with and without OS‐9 overexpression. Proteomics was performed once again using SMMC‐7721 cells with OS‐9 overexpression to further analyze the proteins with altered expression. OS‐9 was overexpressed in the early recurrence group, and OS‐9 overexpression was associated with high serum alpha‐fetoprotein levels and poor recurrence‐free survival in 196 patients with HCC. The invasion and migration abilities of SMMC‐7721 cells were enhanced in the OS‐9 overexpression group. Bioinformatic functional enrichment methods, including Gene Ontology annotation and Kyoto Encyclopedia of Genes and Genomes pathway analysis, revealed that the hypoxia‐inducible factor 1 (HIF‐1) and tumor necrosis factor (TNF) signaling pathways were activated in the OS‐9 overexpression group. The migration and invasion capacities of OS‐9 overexpressed HCC cell line were weakened while treated with HIF‐1α or TNF‐α inhibitors. Conclusion: Our results suggest that the overexpression of OS‐9 is related to HCC recurrence, thereby contributing to the migration and invasion capacities of HCC cell line by regulating the HIF‐1 and TNF pathways. |
format | Online Article Text |
id | pubmed-9315138 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-93151382022-07-27 Proteomics‐based identification of the role of osteosarcoma amplified‐9 in hepatocellular carcinoma recurrence Wei, Xuyong Yang, Mengfan Pan, Binhua Zhang, Xiaobing Lin, Hanchao Li, Wangyao Shu, Wenzhi Wang, Kun Khan, Abdul Rehman Zhang, Xuanyu Cen, Beini Xu, Xiao Hepatol Commun Original Articles Hepatocellular carcinoma (HCC) is one of the most prevalent malignancies; its recurrence is associated with high mortality and poor recurrence‐free survival and is affected by multisystem and multilevel pathological changes. To identify the key proteins associated with tumor recurrence and the underlying mechanisms, proteomic profiling of tumor specimens from early recurrence and nonrecurrence patients was performed in this study. Proteomics was applied to identify differentially expressed proteins during the early recurrence of HCC after surgery. Osteosarcoma amplified‐9 (OS‐9) was discovered, and the correlation between OS‐9 expression and the clinicopathological characteristics of patients was analyzed. Invasion and migration were examined in SMMC‐7721 cells with and without OS‐9 overexpression. Proteomics was performed once again using SMMC‐7721 cells with OS‐9 overexpression to further analyze the proteins with altered expression. OS‐9 was overexpressed in the early recurrence group, and OS‐9 overexpression was associated with high serum alpha‐fetoprotein levels and poor recurrence‐free survival in 196 patients with HCC. The invasion and migration abilities of SMMC‐7721 cells were enhanced in the OS‐9 overexpression group. Bioinformatic functional enrichment methods, including Gene Ontology annotation and Kyoto Encyclopedia of Genes and Genomes pathway analysis, revealed that the hypoxia‐inducible factor 1 (HIF‐1) and tumor necrosis factor (TNF) signaling pathways were activated in the OS‐9 overexpression group. The migration and invasion capacities of OS‐9 overexpressed HCC cell line were weakened while treated with HIF‐1α or TNF‐α inhibitors. Conclusion: Our results suggest that the overexpression of OS‐9 is related to HCC recurrence, thereby contributing to the migration and invasion capacities of HCC cell line by regulating the HIF‐1 and TNF pathways. John Wiley and Sons Inc. 2022-04-16 /pmc/articles/PMC9315138/ /pubmed/35429130 http://dx.doi.org/10.1002/hep4.1952 Text en © 2022 The Authors. Hepatology Communications published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Wei, Xuyong Yang, Mengfan Pan, Binhua Zhang, Xiaobing Lin, Hanchao Li, Wangyao Shu, Wenzhi Wang, Kun Khan, Abdul Rehman Zhang, Xuanyu Cen, Beini Xu, Xiao Proteomics‐based identification of the role of osteosarcoma amplified‐9 in hepatocellular carcinoma recurrence |
title | Proteomics‐based identification of the role of osteosarcoma amplified‐9 in hepatocellular carcinoma recurrence |
title_full | Proteomics‐based identification of the role of osteosarcoma amplified‐9 in hepatocellular carcinoma recurrence |
title_fullStr | Proteomics‐based identification of the role of osteosarcoma amplified‐9 in hepatocellular carcinoma recurrence |
title_full_unstemmed | Proteomics‐based identification of the role of osteosarcoma amplified‐9 in hepatocellular carcinoma recurrence |
title_short | Proteomics‐based identification of the role of osteosarcoma amplified‐9 in hepatocellular carcinoma recurrence |
title_sort | proteomics‐based identification of the role of osteosarcoma amplified‐9 in hepatocellular carcinoma recurrence |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9315138/ https://www.ncbi.nlm.nih.gov/pubmed/35429130 http://dx.doi.org/10.1002/hep4.1952 |
work_keys_str_mv | AT weixuyong proteomicsbasedidentificationoftheroleofosteosarcomaamplified9inhepatocellularcarcinomarecurrence AT yangmengfan proteomicsbasedidentificationoftheroleofosteosarcomaamplified9inhepatocellularcarcinomarecurrence AT panbinhua proteomicsbasedidentificationoftheroleofosteosarcomaamplified9inhepatocellularcarcinomarecurrence AT zhangxiaobing proteomicsbasedidentificationoftheroleofosteosarcomaamplified9inhepatocellularcarcinomarecurrence AT linhanchao proteomicsbasedidentificationoftheroleofosteosarcomaamplified9inhepatocellularcarcinomarecurrence AT liwangyao proteomicsbasedidentificationoftheroleofosteosarcomaamplified9inhepatocellularcarcinomarecurrence AT shuwenzhi proteomicsbasedidentificationoftheroleofosteosarcomaamplified9inhepatocellularcarcinomarecurrence AT wangkun proteomicsbasedidentificationoftheroleofosteosarcomaamplified9inhepatocellularcarcinomarecurrence AT khanabdulrehman proteomicsbasedidentificationoftheroleofosteosarcomaamplified9inhepatocellularcarcinomarecurrence AT zhangxuanyu proteomicsbasedidentificationoftheroleofosteosarcomaamplified9inhepatocellularcarcinomarecurrence AT cenbeini proteomicsbasedidentificationoftheroleofosteosarcomaamplified9inhepatocellularcarcinomarecurrence AT xuxiao proteomicsbasedidentificationoftheroleofosteosarcomaamplified9inhepatocellularcarcinomarecurrence |